Biogen (BIIB +5.8%) rises after ICI analyst Mark Schoenebaum says the company's Tecfidera...

|About: Biogen Inc. (BIIB)|By:, SA News Editor

Biogen (BIIB +5.8%) rises after ICI analyst Mark Schoenebaum says the company's Tecfidera multiple sclerosis drug seems to be "crushing" its competitors. Following just a week on the market, Tecfidera's sales have achieved the same level that Novartis' (NVS) Gilenya reached after three months. However, Schoenebaum warns that it's still too early to make any definitive conclusions about Tecfidera.